Chronic myelogenous leukaemia;Leucémie myéloïde chronique

EMC - Hematologie

Volumn 2, Issue 3, 2005, Pages 187-205

  Leguay, T ^a,b   Mahon, F X ^a,b  

^a HAUT LÉVÊQUE HOSPITAL   (France)

^b INSERM   (France)

Author keywords

Bcr abl transcript; Chronic myelogenous leukaemia; Philadelphia chromosome; Tyrosine kinase inhibitor

Indexed keywords

EID: 32644442896     PISSN: 16386213     EISSN: 16386213     Source Type: Journal    
DOI: 10.1016/j.emch.2005.07.001     Document Type: Short Survey

References (85)

1. Bennett J. Case of hypertrophy of the spleen and liver in which death took place from suppuration of the blood. Edinburg Med Surg J 1845;64:413.
2. Nowell PC. A minute chromosome in human chronic granulocytic leukemia. Science 1960;132:1497.
3. Rowley JD. Letter: A new consistent chromosomal abnormality In chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature 1973; 243:290-3.
4. Yunis JJ. The chromosomal basis of human neoplasla. Science 1983;221:227-36.
5. de Klein A, van Kessel AG, Grosveld G, Bartram CR, Hagemeijer A, Bootsma D, et al. A cellular oncogene Is translocated to the Philadelphia chromosome in chronic myelocytic leukaemia. Nature 1982;300:765-7.
6. Heisterkamp N, Stephenson JR, Groffen J, Hansen PF, de Klein A, Bartram CR, et al. Localization of the c-ab1 oncogene adjacent to a translocation break point in chronic myelocytic leukaemia. Nature 1983;306:239-42.
7. Bartram CR, de Klein A, Hagemeijer A, van Agthoven T, Geurts van Kessel A, Bootsma D, et al. Translocation of c-ab1 oncogene correlates with the presence of a Philadelphia chromosome in chronic myelocytic leukaemia. Nature 1983;306:277-80.
8. Groffen J, Stephenson JR, Heisterkamp N, de Klein A, Bartram CR, Grosveld G. Philadelphia chromosomal break-points are clustered within a limited region, bcr, on chromosome 22. Cell 1984;36:93-9.
9. Shtivelman E, Lifshitz B, Gale RP, Canaani E. Fused transcript of abl and bcr genes in chronic myelogenous leukaemia. Nature 1985;315:550-4.
10. Lugo TG, Pendergast AM, Muller AJ, Witte ON. Tyrosine kinase activity and transformation potency of bcr-abl oncogene products. Science 1990;247:1079-82.
11. Daley GQ, Van Etten RA, Baltimore D. Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome. Science 1990;247:824-30.
12. Biernaux C, Loos M, Sels A, Huez G, Stryckmans P. Detection of major bcr-abl gene expression at a very low level In blood cells of some healthy Individuals. Blood 1995;86: 3118-22.
13. Bose S, Deininger M, Gora-Tybor J, Goldman JM, Melo JV. The presence of typical and atypical BCR-ABL fusion genes In leukocytes of normal individuals: biologic significance and implications for the assessment of minimal residual disease. Blood 1998;92:3362-7.
14. Deininger MW, Bose S, Gora-Tybor J, Yan XH, Goldman JM, Melo JV. Selective Induction of leukemia-associated fusion genes by high-dose Ionizing radiation. Cancer Res 1998;58: 421-5.
15. Thijsen S, Schuurhuis G, van Oostveen J, Ossenkoppele G. Chronic myelold leukemia from basics to bedside. Leukemia 1999;13:1646-74.
16. Hantschel O, Superti-Furga G. Regulation of the c-Abl and Bcr-Abl tyroslne kinases. Nat Rev Mol Cell Biot 2004;5:33-44.
17. Goldman JM, Melo JV. Chronic myeloid leukemia-advances In biology and new approaches to treatment. N Engl J Med 2003;349:1451-64.
18. Melo JV. The diversity of BCR-ABL fusion proteins and their relationship to leukemia phenotype. Blood 1996;88:2375-84.
19. Pane F, Frigeri F, Sindona M, Luciano L, Ferrara F, Cimino R, et al. Neutrophllic-chronic myeloid leukemia: a distinct disease with a specific molecular marker (BCR/ABL with C3/A2 junction). Blood 1996;88:2410-4.
20. Gordon MY, Dowding CR, Riley GP, Goldman JM, Greaves MF. Altered adhesive interactions with marrow stroma of haematopoietic progenitor cells in chronic myeloid leukaemia. Nature 1987;328:342-4.
21. Deininger MW, Goldman JM, Melo JV. The molecular biology of chronic myeloid leukemia. Stood 2000;96:3343-56.
22. Pendergast AM, Muller AJ, Havlik MH, Maru Y, Witte ON. BCR sequences essential for transformation by the BCR-ABL oncogene bind to the ABL SH2 regulatory domain in a non-phosphotyrosine-dependent manner. Cell 1991;66: 161-71.
23. Oda T, Heaney C, Hagopian JR, Okuda K, Griffin JD, Druker BJ. Crkl is the major tyrosine-phosphorylated protein in neutrophils from patients with chronic myelogenous leukemia. J Biol Chem 1994;269:22925-8.
24. Pelicci G, Lanfrancone L, Salcini AE, Romano A, Mele S, Grazia Borrello M, et al. Constitutive phosphorylation of Shc proteins In human tumors. Oncogene 1995;11:899-907.
25. de Groot RP, Raaijmakers JA, Lammers JW, Jove R, Koenderman L. STAT5 activation by BCR-Abl contributes to transformation of K562 leukemia cells. Blood 1999;94: 1108-12.
26. Skorski T, Bellacosa A, Nieborowska-Skorska M, Majewski M, Martinez R, Choi JK, et al. Transformation of hematopoietic cells by BCR/ABL requires activation of a PI-3k/Akt-dependent pathway. EMBOJ 1997;16:6151-61.
27. del Peso L, Gonzalez-Garcia M, Page C, Herrera R, Nunez G. Interleukin-3-induced phosphorylation of BAD through the protein kinase Akt. Science 1997;278:687-9.
28. Dubrez L, Eymin B, Sordet O, Droin N, Turhan AG, Solary E. BCR-ABL delays apoptosis upstream of procaspase-3 activation. Blood 1998;91:2415-22.
29. Amarante-Mendes GP, Naekyung Kim C, Liu L, Huang Y, Perkins CL, Green DR, et al. Bcr-Abl exerts its antiapoptotic effect against diverse apoptotic stimuli through blockage of mitochondrial release of cytochrome C and activation of caspase-3. Blood 1998;91:1700-5.
30. Dai Z, Quackenbush RC, Courtney KD, Grove M, Cortez D, Reuther GW, et al. Oncogenic Abi and Src tyrosine kinases elicit the ubiquitin-dependent degradation of target proteins through a Ras-independent pathway. Genes Dev 1998;12:1415-24.
31. Robledo M, Martinez B, Arranz E, Trujillo MJ, Gonzalez Ageitos A, Rivas C, et al. Genetic instability of microsatellites In hematological neoplasms. Leukemia 1995;9:960-4.
32. Mori N, Morosetti R, Lee S, Spira S, Ben-Yehuda D, Schiller G, et al. Allelotype analysis in the evolution of chronic myelocytic leukemia. Blood 1997;90:2010-4.
33. Silly H, Chase A, Mills KI, Apfelbeck U, Sormann S, Goldman JM, et al. No evidence for microsatellite instability or consistent loss of heterozygosity at selected loci In chronic myeloid leukaemia blast crisis. Leukemia 1994;8:1923-8.
34. Wada C, Shionoya S, Fujino Y, Tokuhiro H, Akahoshi T, Uchida T, et al. Genomic instability of microsatellite repeats and its association with the evolution of chronic myelogenous leukemia. Blood 1994;83:3449-56.
35. Hu Y, Liu Y, Pelletier S, Buchdunger E, Warmuth M, Fabbro D, et al. Requirement of Src kinases Lyn, Hck and Fgr for BCR-ABL1 -induced B-lymphoblastic leukemia but not chronic myeloid leukemia. Nat Genet 2004;36:453-61.
36. LeMaistre A, Lee AAS, Talpaz M, Kantarjian HM, Freireich EJ, Deisseroth AB, et al. Ras oncogene mutations are rare late stage events in chronic myelogenous leukemia. Blood 1989;73:889-91.
37. Tanaka K, Takauchi K, Takechi M, Kyo T, Dohy H, Kamada N. High-frequency of RAS oncogene mutation in chronic myeloid leukemia patients with myeloblastoma. Leuk Lymphoma 1994;13:317-22.
38. Ohyashiki K, Ohyashiki JH, Iwama H, Hayashi S, Shay JW, Toyama K. Telomerase activity and cytogenetic changes in chronic myeloid leukemia with disease progression. Leukemia 1997;11:190-4.
39. Ahuja H, Bar-Eli M, Advani SH, Benchimol S, Cline MJ. Alterations in the p53 gene and the clonal evolution of the blast crisis of chronic myelocytic leukemia. Proc Natl Acad Sci USA 1989:86:6783-7.
40. Jamieson CH, Ailles LE, Dylla SJ, Muijtjens M, Jones C, Zehnder JL, et al. Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML. N Ensl J Med 2004;351:657-67.
41. Speck B, Bortin MM, Champlin R, Goldman JM, Herzig RH, McGlave PB, et al. Allogeneic bone-marrow transplantation for chronic myelogenous leukaemia. Lancet 1984;1: 665-8.
42. Huntly BJ, Bench A, Green AR. Double jeopardy from a single translocation: deletions of the derivative chromosome 9 in chronic myeloid leukemia. Blood 2003;102: 1160-8.
43. Sokal JE, Cox EB, Baccarani M, Tura S, Gomez GA, Robertson JE, et al. Prognostic discrimination in good-risk chronic granulocytic leukemia. Blood 1984;63:789-99.
44. Sokal JE, Baccarani M, Tura S, Fiacchini M, Cervantes F, Rozman C, et al. Prognostic discrimination among younger patients with chronic granulocytic leukemia: relevance to bone marrow transplantation. Blood 1985;66:1352-7.
45. Hasford J, Pfirrmann M, Hehlmann R, Allan NC, Baccarani M, Kluin-Nelemans JC, et al. A new prognostic score for survival of patients with chronic myeloid leukemia treated with Interferon alfa. Writing Committee for the Collaborative CML Prognostic Factors Project Group. J Natl Cancer Inst 1998:90:850-8.
46. Ohnishi K, Ohno R, Tomonaga M, Kamada N, Onozawa K, Kuramoto A, et al. A randomized trial comparing interferon-alpha with busulfan for newly diagnosed chronic myelogenous leukemia in chronic phase. Blood 1995; 86:906-16.
47. Hehlmann R, Heimpel H, Hasford J, Kolb HJ, Pralle H, Hossfeld DK, et al. Randomized comparison of Interferonalpha with busulfan and hydroxyurea in chronic myelogenous leukemia. The German CML Study Group. Blood 1994; 84:4064-77.
48. Silver RT, Woolf SH, Hehlmann R, Appelbaum FR, Anderson J, Bennett C, et al. An evidence-based analysis of the effect of busulfan, hydroxyurea, interferon, and allogeneic bone marrow transplantation in treating the chronic phase of chronic myeloid leukemia: developed for the American Society of Hematology. Blood 1999;94:1517-36.
49. Gratwohl A, Hermans J, Goldman JM, Arcese W, Carreras E, Devergie A, et al. Risk assessment for patients with chronic myeloid leukaemia before allogeneic blood or marrow transplantation. Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Lancet 1998;352:1087-92.
50. Talpaz M, McCredie KB, Mavligit GM, Gutterman JU. Leukocyte interferon-lnduced myeloid cytoreduction In chronic myelogenous leukemia. Stood 1983;62:689-92.
51. Interferon alfa-2a as compared with conventional chemo-therapy for the treatment of chronic myeloid leukemia. The Italian Cooperative Study Group on Chronic Myeloid Leukemia. N Engf J Med 1994;330:820-5.
52. Talpaz M, Kantarjian HM, McCredie K, Trujillo JM, Keating MJ, Gutterman JU. Hematologic remission and cytogenetic improvement induced by recombinant human Interferon alpha A in chronic myelogenous leukemia. N Engl J Med 1986;314:1065-9.
53. Guilhot F, Chastang C, Michallet M, Guerci A, Harousseau JL, Maloisel F, et al. Interferon alfa-2b combined with cytarabine versus interferon alone In chronic myelogenous leukemia. French Chronic Myeloid Leukemia Study Group. N Eng J Med 1997;337:223-9.
54. Kuhr T, Burgstaller S, Apfelbeck U, Linkesch W, Seewann H, Fridrik M, et al. A randomized study comparing interferon (IFN alpha) plus low-dose cytarabine and interferon plus hydroxyurea (HU) in early chronic-phase chronic myeloid leukemia (CML). Leuk Res 2003;27:405-11.
55. Montastruc M, Mahon FX, Faberes C, Marit G, Bilhou-Nabera C, Cony-Makhoul P, et al. Response to recombinant interferon alpha In patients with chronic myelogenous leukemia In a single center: results and analysis of predictive factors. Leukemia 1995;9:1997-2002.
56. Mahon FX, Faberes C, Pueyo S, Cony-Makhoul P, Salmi R, Bolron JM, et al. Response at three months is a good predictive factor for newly diagnosed chronic myeloid leukemia patients treated by recombinant interferonalpha. Stood 1998;92:4059-65.
57. McGlave PB, De Fabritiis P, Deisseroth A, Goldman J, Barnett M, Reiffers J, et al. Autologous transplants for chronic myelogenous leukaemia: results from eight transplant groups. Lancet 1994; 343:1486-8.
58. Buchdunger E, Zimmermann J, Mett H, Meyer T, Muller M, Druker BJ, et al. Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylamlnopyrlmidine derivative. Cancer Res 1996;56:100-4.
59. Druker BJ, Tamura S, Buchdunger E, Ohno S, Segal GM, Fanning S, et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 1996; 2:561-6.
60. Schindler T, Bornmann W, Pellicena P, Miller WT, Clarkson B, Kuriyan J. Structural mechanism for STI-571 inhibition of abelson tyrosine kinase. Science 2000;289:1938-42.
61. Pluk H, Dorey K, Superti-Furga G. Autoinhibition of c-Abl. Cell 2002;108:247-59.
62. Nagar B, Hantschel O, Young MA, Scheffzek K, Veach D, Bornmann W, et al. Structural basis for the autoinhibition of c-Abl tyrosine klnase. Cell 2003;112:859-71.
63. Smith KM, Yacobi R, Van Etten RA. Autoinhibition of Bcr-Abl through its SH3 domain. Mol Cell 2003;12:27-37.
64. Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, Ford JM, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase In chronic myeloid leukemia. N Engl J Med 2001;344:1031-7.
65. Druker BJ, Sawyers CL, Kantarjian H, Resta DJ, Reese SF, Ford JM, et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 2001;344:1038-42.
66. Kantarjian H, Sawyers C, Hochhaus A, Guilhot F, Schiffer C, Gambacortl-Passerini C, et al. Hematologic and cytogenetic responses to imatinib mesylate In chronic myelogenous leukemia. N Engl J Med 2002;346:645-52.
67. Talpaz M, Silver RT, Druker BJ, Goldman JM, Gambacorti-Passerini C, Guilhot F, et al. Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myelold leukemia: results of a phase 2 study. Stood 2002;99:1928-37.
68. Sawyers CL, Hochhaus A, Feldman E, Goldman JM, Miller CB, Ottmann OG, et al. Imatinib Induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. Blood 2002;99:3530-9.
69. O'Brien SG, Guilhot F, Larson RA, Gathmann I, Baccarani M, Cervantes F, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engt J Med 2003;348:994-1004.
70. Druker B, Gathmann I, Bolton AE, Larson RA. Probability and Impact of obtaining a cytogenetic response to imatinib as initial therapy for chronic myeloid leukemia (CML) In chronic phase. Blood 2003;102(11) [abstract].
71. Hahn EA, Glendenning GA, Sorensen MV, Hudgens SA, Druker BJ, Guilhot F, et al. Quality of life in patients with newly diagnosed chronic phase chronic myeloid leukemia on imatinib versus Interferon alfa plus low-dose cytarabine: results from the IRIS Study. J Clin Oncol 2003; 21:2138-46.
72. Hughes TP, Kaeda J, Branford S, Rudzki Z, Hochhaus A, Hensley ML, et al. Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. N Engt J Med 2003; 349:1423-32.
73. Kantarjian H, Schiffer C, Sawyers C, Hochhaus A, Guilhot F, Niederwieser D, et al. Imatinib (Gleevec®) maintains favourable long-term outcomes In chronic-phase chronic myeloid leukemia (CML) for patients failing Interferon-alpha (IFN)- Follow-up of a phase II study. Blood 2003; 102(11) [abstract].
74. van Hoomlssen IC, Hensley ML, Krahnke T, Capdeville R, Ben-Am M, Gathmann I. Imatinib expanded access program (AEP): results of treatment In > 7000 patients with chronic myeloid leukemia (CML). Blood 2003;102(11) [abstract].
75. Etienne G, Cony-Makhoul P, Mahon FX. Imatinib mesylate and gray hair. N Engl J Med 2002;347:446.
76. Mahon FX, Deininger MW, Schultheis B, Chabrol J, Reiffers J, Goldman JM, et al. Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyroslne kinase inhibitor STI571: diverse mechanisms of resistance. Btood 2000;96:1070-9.
77. Le Coutre P, Tassi E, Varella-Garcia M, Barni R, Mologni L, Cabrita G, et al. Induction of resistance to the Abelson Inhibitor STI571 In human leukemic cells through gene amplification. Blood 2000;95:1758-66.
78. Mahon FX, Belloc F, Lagarde V, Chollet C, Moreau-Gaudry F, Reiffers J, et al. MDR1 gene overexpression confers resistance to imatinib mesylate in leukemia cell line models. Btood 2003;101:2368-73.
79. Gorre ME, Mohammed M, Ellwood K, Hsu N, Paquette R, Rao PN, et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 2001;293:876-80.
80. Barthe C, Cony-Makhoul P, Melo JV, Mahon JR. Roots of clinical resistance to STI-571 cancer therapy. Science 2001;293:2163.
81. Branford S, Rudzki Z, Walsh S, Parkinson I, Grigg A, Szer J, et al. Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis. Blood 2003;102:276-83.
82. Corm S, Nicolini F, Bories D, Sorel N, Leguay T, Hayette S, et al. Mutation status of Imatinib Mesylate-Resistant CML patients and Clinical Outcomes: A French Multicenter Retrospective Study for the fiLMCGroup. Blood 2004;:104 [abstract].
83. Donato NJ, Wu JY, Stapley J, Lin H, Arlinghaus R, Aggarwal BB, et al. Imatinib mesylate resistance through BCR-ABL Independence in chronic myelogenous leukemia. Cancer Res 2004; 64:672-7.
84. Bories D, Devergie A, Gardembas-Pain M, Kuentz M, Legros L, Mahon FX, et al. Stratégies thérapeutiques et recommandations pour la prise en charge des patients atteints de leucémie myéloïde chronique. Hématologie 2003; 9:497-512.
85. http://www.cmlsupport.com/. Ce site donne accès au texte intégral de divers articles sur la leucémie myéloïde chronique et son traitement.